文献速递慢病管理预防保健、筛查与疫苗

GLP-1受体激动剂与SGLT2抑制剂:降糖及降低心血管与糖尿病肾病风险

GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease.
PubMed 文献 · J Am Board Fam Med · 2024-01-01

本文综述了GLP-1受体激动剂(GLP-1 RAs)和钠-葡萄糖协同转运蛋白2抑制剂(SGLT2-Is)的作用机制、心血管与肾脏结局证据、禁忌证、不良反应及风险缓解策略。两类药物已成为许多2型糖尿病患者的首选治疗,以降低心血管和肾脏并发症。文章还为基层医生提供了处方、调整和联合用药的实用方法,并考虑患者偏好、耐受性、合并症、费用和可及性。

要点

  • GLP-1 RAs和SGLT2-Is是许多2型糖尿病患者的首选治疗,以降低心血管和肾脏并发症。
  • 综述涵盖两类药物的作用机制、心血管与肾脏结局证据、禁忌证、不良反应及风险缓解策略。
  • 提供基层医生处方、调整和联合用药的实用方法,需考虑患者偏好、耐受性、合并症、费用和可及性。

核心结论

  • 糖尿病药物治疗目标已超越降糖,优先降低心血管疾病和糖尿病肾病风险。
  • GLP-1 RAs和SGLT2-Is已成为许多2型糖尿病患者的首选治疗,以降低心血管和肾脏并发症。

研究设计与样本

  • 综述文章,描述GLP-1 RAs和SGLT2-Is的作用机制、结局证据、禁忌证、不良反应及风险缓解策略。
  • 提供基层医生处方、调整和联合用药的实用方法。

临床怎么用

  • 基层医生应考虑患者偏好、耐受性、合并症、费用和可及性,处方、调整和联合使用GLP-1 RAs和SGLT2-Is。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The landscape of diabetes management has changed, such that the goal of pharmacotherapy extends beyond glucose-lowering to prioritize risk reduction of cardiovascular disease and diabetic kidney disease. Two newer classes of medications, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2-Is), have become first line therapies for many patients with type 2 diabetes to reduce cardiovascular and renal complications of type 2 diabetes. This review article will describe the mechanism of action, evidence for cardiovascular and kidney outcomes, contraindications, adverse effects, and risk mitigation strategies for the GLP-1 RA and SGLT2-I drug classes. In addition, we will provide a practical approach for primary care clinicians to prescribe, adjust, and combine these medication classes, while considering patient preference, tolerability, comorbidities, cost, and availability.

来源:J Am Board Fam Med,查看原文。版权归原作者所有。

引用

  1. Morrison L, Gabison J, Oshman L, et al. GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease. J Am Board Fam Med. 2024. PMID: 39142859. doi:10.3122/jabfm.2023.230455R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。